If you have problems viewing this email, you can view it as a web page.
 
DLA Piper DLA Piper Insights
 
Top of Mind: Life Sciences
January 2020
The challenges facing today’s biotechnology and medical device companies are greater than ever. Companies striving to take promising therapies from the laboratory to the market must protect those therapies from IP, regulatory and reputational risks. Meanwhile, they face steadily increasing pressure on numerous fronts. What new developments are affecting business strategies and bottom lines? Here is a look at eight big topics that life sciences businesses have been thinking about, and how DLA Piper has been covering those stories.
 
 
What starts the avalanche? Earlier triggers for life sciences mass torts in the era of big data and social media
Saher Valiani | Matt Holian | Jill Marinoff
The bar for safety issues to lead to claims that ultimately result in mass tort litigation has never been lower.
Read more
 
The CBD problem: searching for a legal pathway for CBD in foods and supplements
Stefanie Jill Fogel | Maggie Craig
John Packman | Jae Yeon Kim
The state of the laws and regulations in the US, and potential pathways to a resolution.
Read more
 
The cybersecurity of digital medical devices: higher technological capabilities, higher likelihood of liability
Raymond M. Williams | Megan Krebs
Medical device manufacturers are assessing their compliance with HIPAA and FDA’s Draft Guidance and completing a Risk Management Plan.
Read more
 
In Albrecht, US Supreme Court narrows implied preemption of failure-to-warn claims, finds preemption is legal issue for judge, not jury
Ilana H. Eisenstein | Loren H. Brown
Lucas P. Przymusinski | Stan Panikowski
Adam Pierson
The decision clarifies and substantially narrows the scope of preemption under the Wyeth v. Levine “clear evidence” standard.
Read more
 
Effective strategies for challenging master complaints in multidistrict litigation
Jessica C. Wilson
There are a number of creative ways for defendants to challenge master complaints in MDLs.
Read more
 
Explainability: where AI and liability meet
Danny Tobey, M.D., J.D.
Makers and users of AI face a new and interesting problem: what is the acceptable tradeoff between explanation and accuracy?
Read more
 
Local strategies in global class actions for product manufacturers and distributors
Christopher M. Young
Timothy Pfenninger
What global class actions are, how they may affect businesses operating in the global marketplace, and what to consider when a company is the target of such actions.
Read more
 
Supreme Court hears oral argument in Fosamax: key takeaways
Ilana H. Eisenstein | Loren H. Brown
Lucas P. Przymusinski | Stan Panikowski
None of the justices indicated a desire to upset the Wyeth v. Levine framework.
Read more
 
More from DLA Piper
The latest issue of our award-winning quarterly newsletter Intellectual Property and Technology News
Contacts
For more information about our Life Sciences work, please contact any of our global
co-chairs:
Matt Holian
Andrew Gilbert
Marco de Morpugo
In case you missed it
DLA Piper’s global Artificial Intelligence group helps organizations understand the legal and compliance risks arising from the creation and deployment of these emerging and disruptive technologies.
Subscribe
Subscribe
Be the first to read DLA Piper’s insights.
 
Learn more
Learn more
Please visit our Life Sciences page.
 
About us
About us
Find out more about our firm at dlapiper.com.
DLA Piper
dlapiper.com
DLA Piper officesDLA Piper people
Published by DLA Piper LLP (US)
Copyright © 2020 DLA Piper LLP (US), All Rights Reserved

The legislative actions, regulatory activity, and case law discussed in this newsletter are representative, and are not intended as a comprehensive listing of all relevant legal developments.

This bulletin is intended as a general overview and discussion of the subjects dealt with. It is not intended, and should not be used, as a substitute for taking legal advice in any specific situation. DLA Piper will accept no responsibility for any actions taken or not taken on the basis of this publication. Pursuant to applicable Rules of Professional Conduct, it may constitute Attorney Advertising.

DLA Piper LLP (US) is part of DLA Piper, a global law firm, operating through various separate and distinct legal entities. Further details of these entities can be found at dlapiper.com. Review our Privacy Policy for more information about our privacy practices.

You are receiving this communication because you are a valued client or friend of DLA Piper. To unsubscribe from all DLA Piper LLP (US) mailing lists, reply to this message with REMOVE in the subject line. To update your preferences, click here.
 
DLA Piper LLP (US)  |  000142803